Not a Lie — Just Left Unsaid: The Psychology and Structure Behind the "Sin of Omission"

No lies were told. Things were simply left unsaid. What Japan's Ministry of Health, Labour and Welfare sales information surveillance program has documented over seven years is not fabrication — it is omission. Efficacy explained for twenty minutes. Safety information reduced to ten seconds of package insert on screen. Negative Japanese subgroup data withheld until someone asks. Key risks listed in the Risk Management Plan never spoken aloud. The choice not to speak is something no one can directly challenge. That is precisely why it keeps repeating, across organizations and across years.

So What / So Why — The Core of This Issue

So what (what is happening)  The structure is simple. Presentation time is filled with efficacy data. Adverse effects, contraindications, and the important risks in the RMP (Risk Management Plan — the product-specific document governing how risk information is managed) receive either no mention at all or are compressed into the final few seconds. This is not a false statement. It is a choice not to speak. Results from Japanese-population trials that came out negative are never raised unless someone specifically asks. The fact that the approval history includes a hazard ratio above 1.0 in the Japanese subgroup does not get volunteered. The after-the-fact justifications are always ready: "We ran out of time," "It didn't fit in the slides," "We would have answered if asked."

So why (why this is serious)  When a physician decides on a prescription, whatever information is in front of them is all they have. A safety risk that the MR never mentioned may simply not exist in the physician's mind. Even if lactic acidosis is listed as an "important potential risk" in the RMP, if the word is never spoken aloud in the meeting, it never enters the physician's thinking. The guidelines are clear: "Negative information must also be provided." Omission, too, constitutes a deviation.

What makes this category especially serious is that it does not stay within individual judgment calls. The FY2023 and FY2025 surveillance reports both use the phrase "suggesting an intentional organizational effort." When the same omissions are documented across multiple medical institutions for the same drug, it is not a coincidence of individual MRs reaching the same conclusion independently — it points to an organization having decided that this data is not to be disclosed.

The Architecture of Pressure — Who, By When, Against What Numbers

The choice not to speak does not arise in a vacuum. There are pressures that make it a structurally rational choice.

The KPI design problem  MR performance is typically measured by adoption rate, prescription volume, and sales share. The stronger the efficacy pitch, the faster adoption moves and the better the numbers look. Organizations that track the accuracy of safety information delivery as a KPI are rare. If "spending time on safety" does not connect to evaluation, time flows toward efficacy. The incentive structure makes silence the rational choice.

The launch window  For the six to twelve months after a new drug launches, entire sales organizations chase adoption rate figures. In environments where each hospital's adoption status is reported weekly, the motivation to proactively introduce information that might slow adoption is weak. A manager asks whether the target was adopted. Almost no manager asks whether safety information was thoroughly communicated.

Time pressure as a pretext  Ten-to-twenty-minute meetings are a real constraint. But in a pharmacy committee hearing case documented in the FY2023 surveillance report, the hospital had set aside adequate time for explanation — and the negative information still was not provided. Time was not the constraint. The intent was not there. Time pressure functions as a post-hoc justification.

Planned omission with full knowledge of the guidelines  The FY2025 report goes further: "There are cases where it is suspected that representatives are intentionally providing inappropriate information on the premise that they can apologize when called out." They know the guidelines exist, factor in the risk of discovery, and still choose silence. This is not ignorance. It is calculation.

Reconstructing the Internal State — Beliefs, Feelings, Deep Psychology

What follows is an inferential reconstruction of the inner state of those responsible, based on the outward shape of incidents documented in the surveillance program. Read this not as assertion but as reasoned inference: this is what they were probably experiencing, and here is why.

Beliefs (what they held to be true)  "This drug helps patients. The efficacy data is real. The side effects are in the package insert — physicians can check for themselves if they need to. My job is to communicate the product's value accurately, not to read the insert aloud." On the surface this seems reasonable. What it misses is that "they can check for themselves if needed" transfers the responsibility for information delivery onto the recipient.

Feelings (the emotion in the moment)  "If I emphasize safety, the doctor will hesitate. Patients will lose access to a drug that could help them." That fear was likely running in the background in the FY2020 COPD case — where representatives explained that "virtually all COPD patients with asthma comorbidity qualify for this drug" while never mentioning the adverse effect profile. At that stage, the genuine desire to help patients and the drive to protect prescription volume become indistinguishable from each other.

Deep psychology (which of the four drivers was at work)  Multiple drivers operate simultaneously. First, the sin of omission itself — "I didn't lie; I simply didn't say it" — which draws a moral distinction between active falsehood and silence, neutralizing the discomfort. Second, local rationalization — "I'll skip this one slide," "I'll cover this much today" — a series of individual in-the-moment decisions whose cumulative effect on information bias is never examined. Third, motivated reasoning — the conclusion (get the adoption) comes first, and supporting arguments accumulate around it: "It's in the insert," "physicians are specialists." Fourth, externalization of responsibility — "Nobody asked," "The slide structure didn't allow for it," "We didn't have time." The cause is always outside the self. In the cases the FY2025 report describes as "intentional" — where the plan is to apologize if caught — this externalization has become a calculated strategy.

The Real Incidents Behind the Analysis

The three cases below are real incidents documented in the surveillance program reports. Each is presented with the medium, product category, and direct quotation from the report. The internal analysis reconstructed above is not theoretical. The record shows it.

Case 1 — Japanese Subgroup Data Withheld in a Pharmacy Committee Hearing (FY2023)

Case 2 — Twenty-Minute Product Briefing With No Mention of Approval History (FY2025)

Case 3 — Safety Information Gets "The Last Ten Seconds" in a Twenty-Minute Webinar (FY2020)

The FY2025 report goes one step further: "There are cases where it is suspected that representatives are intentionally providing inappropriate information on the premise that they can apologize when called out. This constitutes extremely egregious information provision and is something this program is keeping a close watch on." When the choice not to speak becomes a calculated strategy — one that prices in the probability of discovery — it is no longer a question of individual psychology. It is a question of organizational compliance design.